|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: P4HA2 |
Gene summary for P4HA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | P4HA2 | Gene ID | 8974 |
| Gene name | prolyl 4-hydroxylase subunit alpha 2 | |
| Gene Alias | MYP25 | |
| Cytomap | 5q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O15460 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8974 | P4HA2 | LZE2T | Human | Esophagus | ESCC | 6.16e-03 | 3.41e-01 | 0.082 |
| 8974 | P4HA2 | LZE4T | Human | Esophagus | ESCC | 1.72e-06 | 4.75e-01 | 0.0811 |
| 8974 | P4HA2 | LZE8T | Human | Esophagus | ESCC | 2.27e-05 | 1.40e-01 | 0.067 |
| 8974 | P4HA2 | LZE20T | Human | Esophagus | ESCC | 3.42e-08 | 1.97e-01 | 0.0662 |
| 8974 | P4HA2 | LZE22T | Human | Esophagus | ESCC | 1.61e-08 | 3.15e-01 | 0.068 |
| 8974 | P4HA2 | LZE6T | Human | Esophagus | ESCC | 2.52e-03 | 2.29e-01 | 0.0845 |
| 8974 | P4HA2 | P2T-E | Human | Esophagus | ESCC | 2.05e-36 | 8.17e-01 | 0.1177 |
| 8974 | P4HA2 | P4T-E | Human | Esophagus | ESCC | 8.70e-24 | 8.10e-01 | 0.1323 |
| 8974 | P4HA2 | P5T-E | Human | Esophagus | ESCC | 3.18e-19 | 5.47e-01 | 0.1327 |
| 8974 | P4HA2 | P8T-E | Human | Esophagus | ESCC | 9.04e-14 | 1.38e-01 | 0.0889 |
| 8974 | P4HA2 | P9T-E | Human | Esophagus | ESCC | 5.46e-07 | 3.05e-01 | 0.1131 |
| 8974 | P4HA2 | P10T-E | Human | Esophagus | ESCC | 8.21e-10 | 2.48e-01 | 0.116 |
| 8974 | P4HA2 | P11T-E | Human | Esophagus | ESCC | 4.87e-22 | 1.20e+00 | 0.1426 |
| 8974 | P4HA2 | P12T-E | Human | Esophagus | ESCC | 4.59e-22 | 5.66e-01 | 0.1122 |
| 8974 | P4HA2 | P15T-E | Human | Esophagus | ESCC | 4.37e-29 | 7.58e-01 | 0.1149 |
| 8974 | P4HA2 | P16T-E | Human | Esophagus | ESCC | 1.14e-22 | 4.83e-01 | 0.1153 |
| 8974 | P4HA2 | P17T-E | Human | Esophagus | ESCC | 3.54e-13 | 1.08e+00 | 0.1278 |
| 8974 | P4HA2 | P19T-E | Human | Esophagus | ESCC | 1.50e-14 | 1.39e+00 | 0.1662 |
| 8974 | P4HA2 | P20T-E | Human | Esophagus | ESCC | 1.14e-30 | 7.88e-01 | 0.1124 |
| 8974 | P4HA2 | P21T-E | Human | Esophagus | ESCC | 3.45e-40 | 8.86e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:0022900110 | Esophagus | ESCC | electron transport chain | 133/8552 | 175/18723 | 2.18e-16 | 1.67e-14 | 133 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:00181263 | Esophagus | ESCC | protein hydroxylation | 23/8552 | 27/18723 | 2.60e-05 | 2.19e-04 | 23 |
| GO:00195114 | Esophagus | ESCC | peptidyl-proline hydroxylation | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
| GO:00184014 | Esophagus | ESCC | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
| GO:002290012 | Liver | Cirrhotic | electron transport chain | 111/4634 | 175/18723 | 1.94e-27 | 1.52e-24 | 111 |
| GO:00182084 | Liver | Cirrhotic | peptidyl-proline modification | 26/4634 | 58/18723 | 6.65e-04 | 5.04e-03 | 26 |
| GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
| GO:002290022 | Liver | HCC | electron transport chain | 134/7958 | 175/18723 | 3.32e-20 | 4.68e-18 | 134 |
| GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
| GO:0018126 | Liver | HCC | protein hydroxylation | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
| GO:002290018 | Oral cavity | OSCC | electron transport chain | 126/7305 | 175/18723 | 6.65e-19 | 8.42e-17 | 126 |
| GO:000609118 | Oral cavity | OSCC | generation of precursor metabolites and energy | 286/7305 | 490/18723 | 1.45e-18 | 1.71e-16 | 286 |
| GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
| GO:00181262 | Oral cavity | OSCC | protein hydroxylation | 22/7305 | 27/18723 | 7.89e-06 | 8.49e-05 | 22 |
| GO:00195113 | Oral cavity | OSCC | peptidyl-proline hydroxylation | 13/7305 | 15/18723 | 2.07e-04 | 1.36e-03 | 13 |
| GO:00184013 | Oral cavity | OSCC | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | 9/7305 | 10/18723 | 1.36e-03 | 6.62e-03 | 9 |
| GO:002290019 | Oral cavity | LP | electron transport chain | 108/4623 | 175/18723 | 2.21e-25 | 9.90e-23 | 108 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0033021 | Liver | HCC | Arginine and proline metabolism | 33/4020 | 50/8465 | 6.28e-03 | 1.77e-02 | 9.83e-03 | 33 |
| hsa0033031 | Liver | HCC | Arginine and proline metabolism | 33/4020 | 50/8465 | 6.28e-03 | 1.77e-02 | 9.83e-03 | 33 |
| hsa0033010 | Oral cavity | OSCC | Arginine and proline metabolism | 30/3704 | 50/8465 | 1.50e-02 | 3.26e-02 | 1.66e-02 | 30 |
| hsa0033013 | Oral cavity | OSCC | Arginine and proline metabolism | 30/3704 | 50/8465 | 1.50e-02 | 3.26e-02 | 1.66e-02 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| P4HA2 | SNV | Missense_Mutation | rs199899764 | c.910N>T | p.Arg304Cys | p.R304C | O15460 | protein_coding | deleterious(0) | possibly_damaging(0.556) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| P4HA2 | insertion | Nonsense_Mutation | novel | c.1550_1551insTGAGATGTTTCAGTGAACCAAAGTTCTGATACCTTGTTTACAT | p.Trp517CysfsTer6 | p.W517Cfs*6 | O15460 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| P4HA2 | insertion | Frame_Shift_Ins | novel | c.1554_1555insG | p.His519AlafsTer2 | p.H519Afs*2 | O15460 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| P4HA2 | insertion | Frame_Shift_Ins | novel | c.1553_1554insTGGAGAAATGAATGTTTGTCTGGAGCAGAGGGAGACCATACTAGGG | p.His519GlyfsTer17 | p.H519Gfs*17 | O15460 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| P4HA2 | deletion | Frame_Shift_Del | novel | c.1048delN | p.Ile350SerfsTer38 | p.I350Sfs*38 | O15460 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| P4HA2 | SNV | Missense_Mutation | rs778443240 | c.1340C>T | p.Thr447Met | p.T447M | O15460 | protein_coding | deleterious(0) | possibly_damaging(0.523) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| P4HA2 | SNV | Missense_Mutation | novel | c.76N>A | p.Ser26Thr | p.S26T | O15460 | protein_coding | deleterious(0) | possibly_damaging(0.751) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| P4HA2 | SNV | Missense_Mutation | c.713N>G | p.Pro238Arg | p.P238R | O15460 | protein_coding | deleterious(0) | possibly_damaging(0.464) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| P4HA2 | SNV | Missense_Mutation | rs200158840 | c.215N>T | p.Ser72Leu | p.S72L | O15460 | protein_coding | deleterious(0.01) | possibly_damaging(0.643) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| P4HA2 | SNV | Missense_Mutation | c.269T>C | p.Val90Ala | p.V90A | O15460 | protein_coding | tolerated(0.06) | benign(0.259) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |